NCT00357448 2019-05-14
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
University of Washington
Phase 1 Completed
Clinical Trials
11 trialsNCT00425672 2018-12-05
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
University of Washington
Phase 1/2 Completed
NCT00880360 2018-03-27
ONTAK
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT00460109 2017-04-18
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00082940 2017-01-19
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00337987 2015-02-27
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Yale University
Phase 2 Completed
NCT00228358 2014-11-11
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
University of Washington
Phase 1 Completed
NCT00299689 2014-09-05
Phase II Trial of Ontak With Metastatic Melanoma
James Graham Brown Cancer Center
Phase 2 Completed
NCT00278369 2013-05-22
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00128622 2012-11-12
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
Duke University
Phase 1 Completed
NCT00493129 2012-02-08
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
M.D. Anderson Cancer Center
Phase 2 Completed